Prospects for eradication of meningococcal disease

Archives of Disease in Childhood

Volumn 97, Issue 11, 2012, Pages 993-998

  Nadel, Simon ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; PARACETAMOL; POLYSACCHARIDE VACCINE;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE CONTROL; ENDEMIC DISEASE; GRAM NEGATIVE BACTERIUM; HEMIPLEGIA; HUMAN; IMMUNOGENICITY; INCIDENCE; INTENSIVE CARE UNIT; MEMBRANE VESICLE; MENINGITIS; MENINGOCOCCOSIS; MORBIDITY; NEISSERIA MENINGITIDIS; PANDEMIC; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SKIN DEFECT; UNITED KINGDOM;

DISEASE ERADICATION; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84868212460     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-302036     Document Type: Review

References (67)

1. Davies EG. The immunology of neonates and children and its relation to susceptibility to infection. In: Nadel S, ed. Infectious Diseases in the Pediatric Intensive Care Unit. Berlin: Springer, 2008:1-58.
2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-210. (Pubitemid 46977462)
3. World Health Organization. New and under-utilized vaccines implementation (NUVI): bacterial meningitis (online). http://www.who.int/nuvi/meningitis/en/ index. html (accessed 13 Apr. 2011).
4. World Health Organization. Meningococcal meningitis (online). http://www.who. int/mediacentre/factsheets/fs141/en/index.html (accessed 18 Feb. 2011).
5. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:317-28.
6. Martin M, Casellas JM, Madhi SA, et al. Impact of Haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 2004;23:842-7. (Pubitemid 40221028)
7. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001;344:1378-88.
8. Centers for Diseases Control and Prevention. Meningococcal disease: technical and clinical information (online). http://www.cdc.gov/meningitis/ clinical-info.html (accessed 17 Aug. 2011).
9. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;24:B51-63.
10. Centers for Diseases Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network. Neisseria meningitidis, 2006 (online). http://www.cdc.gov/abcs/reports-findings/ survreports/mening06.pdf (accessed 17 Aug. 2011).
11. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14. (Pubitemid 46058815)
12. The European Union Invasive Bacterial Infections Surveillance Network. Invasive meningococcal disease (online). http://www.ecdc.europa.eu/en/ publications/Publications/1011-SUR-Annual-Epidemiological-Report-on- Communicable-Diseases-in-Europe.pdf age=149 (accessed 21 Feb. 2011).
13. EU-IBIS Network. Invasive Neisseria Meningitidis in Europe 2006. London: Health Protection Agency, 2006. http://www.hpa-bioinformatics.org.uk/euibis/ documents/2006-meningo.pdf (accessed 17 Aug. 2011).
14. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010;50:S37-44.
15. Health Protection Agency. http://www.hpa.org.uk/hpr/infections/ immunisation. htm (accessed 24 Feb. 2012).
16. Wright C. Counting the cost of meningitis. Presented at the Meningitis Research Foundation Conference 2011. November 8th/9th 2011, London, UK: Royal Society of Medicine.
17. Garralda ME, Gledhill J, Nadel S, et al. Longer-term psychiatric adjustment of children and parents after meningococcal disease. Pediatr Crit Care Med 2009;10:675-80.
18. Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988;16:55-9.
19. Borrow R, Joseph Andrews N, et al. Reduced antibody response to revaccination and men with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2001;19:1129-32. (Pubitemid 32008278)
20. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-4. (Pubitemid 30131856)
21. Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine 2006;24:4692-700. (Pubitemid 43776790)
22. Centers for Diseases Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1-21.
23. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2005;54:1-21.
24. World Health Organization. Meningitis A conjugate vaccine. Wkly Epidemiol Rec 2011;86:42-3.
25. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England. BMJ 2003;326:365-6. (Pubitemid 36241472)
26. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002;186:1353-7. (Pubitemid 35193017)
27. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005;24:128-31. (Pubitemid 40250770)
28. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91. (Pubitemid 351977021)
29. JCVI statement on the use of meningococcal C vaccines in the routine childhood immunisation programme. 29 January 2012.
30. Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990;162:1316-23.
31. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/2004: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006;55:887-96. (Pubitemid 43974695)
32. Panatto D, Amicizia D, Lai PL, et al. Neisseria meningitidis B vaccines. Expert Rev Vaccines 2011;10:1337-51.
33. Oliver KJ, Reddin KM, Bracegirdle P, et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002;70:3621-6. (Pubitemid 34666000)
34. Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011;29:1413-20.
35. Zollinger WD, Donets MA, Schmiel DH, et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010;28:5057-67.
36. Schneider MC, Exely RM, Ram S, et al. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007;15:233-40. (Pubitemid 46671509)
37. Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 2010;6:e1001027.
38. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
39. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH 1991;14:195-207.
40. Milagres LG, Gorla MC, Sacchi CT, et al. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998;66:4755-61. (Pubitemid 28453078)
41. Milagres LG, Gorla MC, Rebelo MC, et al. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine. FEMS Immunol Med Microbiol 2000;28:319-27. (Pubitemid 30417446)
42. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-7. (Pubitemid 29200936)
43. Wedege E, Høiby EA, Rosenqvist E, et al. lmmune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998;66:3223-31. (Pubitemid 28303120)
44. Oster P, Lennon D, O'Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6. (Pubitemid 40341449)
45. Devoy AF, Dyet KH, Martin DR. Stability of PorA during a meningococcal disease epidemic. J Clin Microbiol 2005;43:832-7. (Pubitemid 40256042)
46. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7. (Pubitemid 36091989)
47. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-18.
48. Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000;287:1809-15. (Pubitemid 30143964)
49. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010;33:530-41.
50. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9. (Pubitemid 44148381)
51. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
52. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82.
53. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
54. Donnelly J, Medini D, Giuliani M, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Presented at Meningitis Research Foundation Conference 2011;8-9 November 2011; London.
55. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5.
56. Peter Dull. Novartis vaccines. Presented at: Meningitis Research Foundation Conference 2011;8-9 November 2011; London.
57. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009;374:1339-50.
58. Sandbu S, Feiring B, Oster P, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007;14:1062-9. (Pubitemid 47518071)
59. Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009;155:4155-69.
60. Richmond P, Marshall H, Sheldon E, et al. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Presented at The 17th International Pathogenic Neisseria Conference; 11-16 September 2010; Banff, Canada.
61. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010;28:6086-93.
62. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99. (Pubitemid 36350873)
63. Welsch JA, Rossi R, Comanducci M, et al. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004;172:5606-15. (Pubitemid 38542063)
64. Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009;77:292-9.
65. Horton RE, Stuart J, Christensen H, et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol Infect 2005;133:883-9. (Pubitemid 41478974)
66. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:853-61.
67. Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C Disease. Hum Vaccin 2011;7(Suppl):68-74.